Patents Assigned to Ablynx N.V.
  • Patent number: 10618966
    Abstract: The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise the amino acid sequence, nucleic acids that encode the amino acid sequences, compounds or constructs, pharmaceutical compositions comprising the amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: April 14, 2020
    Assignee: Ablynx N.V.
    Inventors: Joost Alexander Kolkman, Els Anna Alice Beirnaert
  • Publication number: 20200079844
    Abstract: The present invention relates to improved Nanobodies™ against Tumor Necrosis Factor-alpha (TNF-alpha), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.
    Type: Application
    Filed: May 28, 2019
    Publication date: March 12, 2020
    Applicant: Ablynx N.V.
    Inventor: Els Anna Alice Beirnaert
  • Publication number: 20200062834
    Abstract: The present invention relates to an improved method for the manufacture of immunoglobulin single variable domains. More specifically, the present invention relates to a method of producing immunoglobulin single variable domains in which the proportion of carbamylated variants is strongly reduced or absent and to improved immunoglobulin single variable domains obtainable by methods of the present invention.
    Type: Application
    Filed: August 2, 2019
    Publication date: February 27, 2020
    Applicant: Ablynx N.V.
    Inventors: Ann Brige, Bart Walcarius, Yves Meyvis, Mauro Sergi
  • Patent number: 10561805
    Abstract: Methods are provided for the treatment of RSV infections in young children. More specifically, methods are provided wherein polypeptides that bind F protein of hRSV and that neutralize RSV infection are administered to the lungs of young children at specific dose regimens.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: February 18, 2020
    Assignees: ABLYNX N.V., VECTURA GMBH
    Inventors: Koen Allosery, Erik Depla, Martin Huber, Tobias Kolb, Bernhard Müllinger, Massimiliano Germani, Juliane Schick, Maria-Laura Sargentini
  • Patent number: 10550174
    Abstract: The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: February 4, 2020
    Assignee: Ablynx N.V.
    Inventors: Catelijne Stortelers, Peter Vanlandschoot, Erik Depla, Jose Melero
  • Patent number: 10544216
    Abstract: The present invention relates to biological materials against P2X7 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the biological materials of the present invention inhibit the biological activity of the P2X7 receptor, such as activation by ATP.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: January 28, 2020
    Assignees: Ablynx N.V., University Medical Center Hamburg-Eppendorf
    Inventors: Welbeck Owusu Danquah, Friedrich Nolte, Catelijne Stortelers, Toon Laeremans
  • Patent number: 10544211
    Abstract: The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor alpha (“TNF” or “TNF-alpha”). In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVDs”) binding to tumor necrosis factor alpha, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs, collectively TNF binders. Other aspects, embodiments, features, uses and advantages of the invention will be clear to the skilled person based on the disclosure herein.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: January 28, 2020
    Assignee: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Joachim Boucneau, Peter Casteels, Gino Van Heeke
  • Patent number: 10512739
    Abstract: An inhalation device, assembly or system can include a kit and a pharmaceutical composition. The device can be adapted for administering therapeutic aerosols to pediatric patients, including neonates, infants or toddlers. The device can further include a vibrating mesh aerosol generator that can be insertable into a flow channel of the inhalation device through a lateral opening, and a valved face mask. The device can be connectable to a gas source through which a gas, such as oxygen, can be received into the flow channel at a low flow rate.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: December 24, 2019
    Assignees: VECTURA GMBH, ABLYNX N.V.
    Inventors: Koen Allosery, Martin Huber, Tobias Kolb, Bernhard Müllinger, Juliane Schick, Erik Depla
  • Publication number: 20190382485
    Abstract: T cell recruiting polypeptides are provided that bind CD3 on a T cell. The polypeptides can be used in methods for treatment of cancers.
    Type: Application
    Filed: May 13, 2016
    Publication date: December 19, 2019
    Applicant: Ablynx N.V.
    Inventors: Annelies Roobrouck, Diane Van Hoorick, João Vieira
  • Publication number: 20190367597
    Abstract: The present invention relates to amino acid sequences that can bind to serum albumin. In particular, the present invention relates to immunoglobulin single variable domains, and in particular heavy-chain immunoglobulin single variable domains, that can bind to serum albumin. The invention also relates to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise at least one of the immunoglobulin single variable domains binding to serum albumin that are described herein.
    Type: Application
    Filed: January 17, 2018
    Publication date: December 5, 2019
    Applicant: Ablynx N.V.
    Inventors: Stephanie STAELENS, Soren STEFFENSEN, Erika MORIZZO, An CERDOBBEL
  • Publication number: 20190367598
    Abstract: The present invention relates to amino acid sequences that can bind to serum albumin. In particular, the present invention relates to immunoglobulin single variable domains, and in particular heavy-chain immunoglobulin single variable domains, that can bind to serum albumin. The invention also relates to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise at least one of the immunoglobulin single variable domains binding to serum albumin that are described herein.
    Type: Application
    Filed: January 17, 2018
    Publication date: December 5, 2019
    Applicant: Ablynx N.V.
    Inventors: Stephanie STAELENS, Soren STEFFENSEN, Erika MORIZZO, An CERDOBBEL
  • Publication number: 20190367596
    Abstract: The present invention relates to amino acid sequences that can bind to serum albumin. In particular, the present invention relates to immunoglobulin single variable domains, and in particular heavy-chain immunoglobulin single variable domains, that can bind to serum albumin. The invention also relates to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise at least one of the immunoglobulin single variable domains binding to serum albumin that are described herein.
    Type: Application
    Filed: December 7, 2017
    Publication date: December 5, 2019
    Applicant: Ablynx N.V.
    Inventors: Stephanie Staelens, Soren Steffensen, Erika Morizzo, Raf Ponsaerts, Ingrid Ottevaere, An Cerdobbel
  • Publication number: 20190292267
    Abstract: The present invention relates to bispecific polypeptides that are directed against the cellular receptor CD4 as well as a cellular co-receptor for HIV. Said polypeptides may be used to prevent human cell entry of HIV.
    Type: Application
    Filed: March 7, 2019
    Publication date: September 26, 2019
    Applicant: Ablynx N.V.
    Inventors: Hugo Soares, Dominique Schols, Peter Vanlandschoot, Philippe Van Rompaey, Catelijne Stortelers
  • Patent number: 10407492
    Abstract: The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: September 10, 2019
    Assignee: Ablynx N.V.
    Inventors: Catelijne Stortelers, Peter Vanlandschoot, Erik Depla, Jose Melero
  • Patent number: 10392440
    Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: August 27, 2019
    Assignee: Ablynx N.V.
    Inventors: Els Anna Alice Beirnaert, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy
  • Publication number: 20190211101
    Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: December 12, 2018
    Publication date: July 11, 2019
    Applicant: Ablynx N.V.
    Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
  • Publication number: 20190194302
    Abstract: Methods are provided for the manufacture of polypeptides comprising at least one immunoglobulin variable domain that result in an increased yield. The methods are based on simultaneous enhancement of one or more auxiliary proteins in the host.
    Type: Application
    Filed: February 10, 2017
    Publication date: June 27, 2019
    Applicant: Ablynx N.V.
    Inventors: Peter SCHOTTE, Manu DE GROEVE
  • Publication number: 20190195866
    Abstract: The present invention generally relates to improved pharmacokinetic assays for measuring levels of immunoglobulin single variable domains (also referred to herein as “ISVs” or “ISVDs”) and of proteins and polypeptides that comprise at least one ISV (as further described herein) in biological samples.
    Type: Application
    Filed: June 21, 2017
    Publication date: June 27, 2019
    Applicant: Ablynx N.V.
    Inventors: Veerle Snoeck, Lieselot Bontinck, Sofie Poelmans, Kjell Mortier, Marie-Ange Buyse, Lies Dekeyzer, Judith Baumeister
  • Publication number: 20190144531
    Abstract: Processes and methods of purifying or separating Single Domain Antigen Binding (SDAB) molecules that include one or more single binding domains (e.g., one or more nanobody molecules), substantially devoid of a complementary antibody domain and an immunoglobulin constant region, using Protein A-based affinity chromatography, are disclosed.
    Type: Application
    Filed: September 26, 2018
    Publication date: May 16, 2019
    Applicant: Ablynx N.V.
    Inventors: Paul R. Brown, Scott Andreas Tobler, Andrew M. Wood, Austin Wayne Boesch
  • Publication number: 20190127447
    Abstract: Methods are provided for the treatment of RSV infections in young children. More specifically, methods are provided wherein polypeptides that bind F protein of h RSV and that neutralize RSV infection are administered to the lungs of young children at specific dose regimens.
    Type: Application
    Filed: May 2, 2017
    Publication date: May 2, 2019
    Applicant: Ablynx N.V.
    Inventors: Maria-Laura Sargentini-Maier, Koen Allosery, Erik Depla, Massimiliano Germani